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The oncogene MDM2 located on chromosome 12 is amplified in
solid tumours (Fakharzadeh et al, 1991; Oliner et al, 1992).
Overexpression of the gene is an important tumorigenic mecha-
nism immortalizing rat fibroblasts (Finlay, 1993) and is associated
with tumour progression in leukaemias (Bueso-Ramos et al,
1993).  MDM2 encodes a phosphoprotein with multiple functions.
The N-terminus of MDM2 protein forms a complex with the
central tumour suppressor p53, thus blocking the trans-activating
functions of p53 (Momand et al, 1992). The central acidic domain
of MDM2 interacts with the TATA-binding protein TBP
(Leveillard and Wasylyk, 1997). The C-terminus of MDM2
contains three zinc-finger motifs, two of them forming a RING
finger structure (Boddy et al, 1994) which binds the basal tran-
scription factor TAFII250 (Leveillard and Wasylyk, 1997). These
findings suggest an important role of MDM2 protein in regulation
of cell division and transcriptional control.
So far, only a few publications are available on the GAGE-1 and
GAGE-2 genes. Both genes are members of a family of closely
related genes coding for the MAGE-GAGE-and BAGE-antigens
presented by MHC class I molecules (Van der Bruggen et al, 1991;
Gaugler et al, 1994; Böel et al, 1995). The GAGE-1 and GAGE-2
tumour-associated antigens are recognized by autologous cytolytic
T lymphocytes (Van den Eynde et al, 1995) and are expressed in
tumour entities such as ovarian, colorectal and lung carcinomas
(Van den Eynde et al, 1995; Russo et al, 1996). The GAGE-1 and
GAGE-2 antigens are also testis antigens because of their absence
in normal tissue except for testis (Van den Eynde et al, 1995).
Therefor, they are proposed as diagnostic markers.
The gene FHIT, a new member of the human histidine triad
gene family, has been isolated recently (Ohta et al, 1996). This
gene is located on the short arm of chromosome 3 in a region
carrying multiple tumour suppressor genes presumably involved
in cancer development (LaForgia et al, 1991; Kastury et al, 1996).
Genetic studies have defined this locus as unstable. FHIT contains
fragile sites, one of which represents the t(3;8) breakpoint
observed in familial renal cell carcinoma (Cohen et al, 1979; Wang
and Perkins, 1984), while the other one, designated FRA3B, was
originally described as one of the most fragile sites of the human
genome (LeBeau and Rowley, 1984). FHIT is subjected to genetic
alterations such as homozygous deletions or splicing abnormali-
ties. Many samples obtained from malignant tumours of the
oesophagus, stomach, colon, cervix, breast, and head and neck
revealed aberrant FHIT transcripts containing exon deletions and
insertions (Negrini et al, 1996; Sozzi et al, 1996; Thiagalingam
et al, 1996; Virgilio et al, 1996; Gemma et al, 1997; Hendricks
et al, 1997). Furthermore, in small cell lung carcinomas and non-
small cell lung cancers, microsatellite polymorphism analyses,
loss of hybridization (LOH) analyses and hybridization experi-
ments revealed characteristic alterations within FHIT (Fong et al,
1997; Sozzi et al, 1996, 1997) supposed to represent initial events
of lung cancer development (Sozzi et al, 1997).
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several human malignancies. Their analyses might be of diagnostic importance. Therefore, malignant hepatocytes derived from
hepatocellular carcinoma (HCC) tissue as well as non-malignant hepatocytes derived from focal nodular hyperplasia (FNH) were studied.
Samples containing normal human hepatocytes (HC) served as controls. Cellular material was obtained by fine-needle aspiration biopsy
guided by ultrasound. Cells were analysed for expression and mutation of the oncogene MDM2, the genes GAGE-1, -2 coding for tumour-
associated antigens and the candidate tumour suppressor gene FHIT. Different patterns of non-mutant FHIT transcripts including precise
deletion of exons were found in 7/10 HCC, 2/10 FNH and 2/10 HC. However, expression of non-mutant GAGE-1, -2 RNA was demonstrated
exclusively in 6/10 HCC samples. Further genetic features specific of HCC were point mutations in a zinc-finger motif of MDM2 (3/10 HCC
samples). Neither GAGE-1, -2 expression nor MDM2 mutations were observed in the FNH samples, or in normal hepatocytes. Our findings
suggest that occurrence of variable FHIT transcripts is not restricted to hepatic malignant tumours. In contrast, MDM2 mutations and GAGE-
1, -2 expression were associated with HCC specimens. Therefore, the RT-PCR assays for GAGE-1, -2 and MDM2 might be useful adjuncts
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Correspondence to: T Schlott This study is a part of the doctoral dissertation of cand. med. K AhrensThe aim of the present study was to search for genetic alter-
ations that might serve as markers in cytologically based diagnosis
of malignant hepatic tumours. The data published so far regarding
MDM2, GAGE-1, -2 and FHIT suggest that analysis of the latter
might contribute to the differentiation of malignant hepatocytes
[i.e. derived from hepatocellular carcinoma (HCC)] from benign
proliferating hepatocytes [i.e. focal nodular hyperplasia (FNH)]
and normal hepatocytes respectively. Therefore, a combined
expression assay for FHIT, GAGE-1, -2, and MDM2 in cells
obtained by fine-needle aspiration was used and these genetic data
were correlated with clinicopathological features.
MATERIALS AND METHODS
Sample collection
Slides examined were obtained by ultrasound-guided fine-needle
aspiration from ten patients with HCC (five women, five men)
and ten patients with FNH (eight women, two men). In all cases,
cytodiagnosis was subsequently confirmed by histological and/or
clinical findings. The slides were routinely stained according to
May–Grünwald–Giemsa and stored up to 3 years. Additionally,
ten controls (hepatocyte cultures, fetal hepatocytes, specimens
from liver autopsy) were analysed. Two cell lines isolated from
fresh HCC samples described in the previous study of Schlott et al
(1997) were used for establishing the tests.
RNA isolation and cDNA amplification
Glass slide smears were kept in xylene for 2 days to remove cover
slips. The cells were scraped into sterile Eppendorf microfuge
tubes with razor-blades and washed once with xylene and twice
with ethanol (96%, v/v) to remove any traces of xylene. Cells and
cellular debris were harvested by centrifugation (500 rpm at 4°C)
and dried in a speed vacuum concentrator (Eppendorf, Hamburg,
Germany). RNA was isolated from malignant and non-malignant
hepatocytes with the RNeasy Total RNA Kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions. RNA was
eluted from the affinity columns and concentrated in a final
volume of 5 ml water by vacuum centrifugation. To inhibit degra-
dation of RNA, plastic ware and solutions were treated with 0.1%
(w/v) DEPC (Sigma, Munich, Germany). Oligonucleotide primers
purified by high-pressure liquid chromatography were supplied by
MWG Biotech (Munich, Germany). Amplification of RNA tran-
scripts was performed with a GeneAmp RNA-PCR Kit according
to the manufacturer’s prescriptions (Perkin-Elmer, Weiterstadt,
Germany). Polymerase chain reaction (PCR) was performed on a
DNA thermal cycler UNOII (Biometra, Goettingen, Germany)
using thin-walled reaction tubes. Two microliters of RNA solution
were used for b-actin,  MDM2,  GAGE-1,  -2 and  FHIT reverse
transcriptase (RT)-PCR. Random hexamers supplied by the manu-
facturer were used for synthesis of cDNA.
Total RNA extracted from multiple cytological specimens of
each patient were pre-screened for b-actin RNA by PCR. Final
analysis was performed on the samples containing non-degraded
b-actin RNA.  b-actin-primers were 5¢-CTACAATGAGC-
TGCG-TGTGGC-3¢ (sense strand) and 5¢-CAGGTCCA-
GACGCAGGATGGC-3¢ (antisense strand) yielding a 240 base
pair (bp) product (Albitar et al, 1989). Cycling conditions have
been described previously (Schlott et al, 1997).
MDM2 primers used for amplifying the complete C-terminal
nucleotide stretch including the zinc finger sequence and the
RING finger were 5¢-CGACTAGAAGATTATAGCC-3¢ (sense
primer) and 5¢-ATTGGTTGTCTATAGG-3¢ (antisense primer).
The amplimers yielded a product of 684 bp. The underlying
temperature cycling schedule was initiated by a melting step
lasting 7 min at 95°C and terminated by a final step at 72°C lasting
10 min. Forty runs were performed. Each run consisted of melting
cycle (94°C, 30 s), primer annealing cycle (56°C, 90 s), and exten-
sion cycle (72°C, 90 s).
Primer 5¢-GACCAAGACGCTACGTAG-3¢ (sense strand) and
primer 5¢-CCATCAGGACCATCTTCA-3¢ (antisense strand) were
used for amplification of a nucleotide sequence shared by GAGE-
1 and GAGE-2 RNA. These primers give a 244 bp product. All
PCR procedures were performed as described (Van den Eynde et
al, 1995).
Primers used for amplification of FHIT sequences were 5¢-
CATCCTGGAAGCTTTGAAGCT-3¢ (exon 3, sense primer 1,
position –201 to –223), 5¢-TCCGTAGTGCTATCTACATCC-3¢
(exon 3, sense primer 2, position –142 to –162), and 5¢-TCCTCT-
GATCTCCAAGAGGC-3¢ (exon 9, antisense primer, position 379
to 398). The sequences were selected from published data of Ohta
et al (1996). The combination sense primer 1/antisense primer
yielded a 599 bp fragment, combination sense primer 2/antisense
primer a 561 bp fragment. Following an initial denaturing step at
95°C for 7 min, cDNA was amplified 40 times in three tempera-
ture cycles. In each amplification series a 30-s melting cycle at
95°C was followed by a combined annealing cycle for 1 min at
60°C, and an extension cycle for 2 min at 72°C. The final round
was completed with a primer extension for 240 s at 72°C. Cycling
conditions of the second round PCR differed from the first one in
annealing temperature (62°C) and temperature cycle number (30
cycles).
Gel electrophoresis and cDNA sequencing
For visualization, 5 ml of each PCR assay (final volume 100 ml)
was separated on a 3% (w/v) agarose gel containing 0.5 mg
ethidium bromide per ml. The gel was registered by means of a
CCD camera (Biometra, Goettingen, Germany). FHIT-PCR prod-
ucts were separated on 3% low-melting agarose (Biozym, Hameln,
Germany) and cut from the gel. The QIAEX II Gel Extraction Kit
(QIAGEN, Hilden, Germany) was used to purify the FHIT cDNA.
The GAGE-1, -2 and MDM2 amplification products were purified
with the QIAquick PCR Purification Kit (QIAGEN, Hilden,
Germany).
A total of 200 ng of isolated DNA were labelled with the
PRISM Ready Dye Deoxy Terminator Cycle Sequencing Kit
(Applied Biosystems, Weiterstadt, Germany) according to the
manufacturer’s instructions and analysed in an Applied
Biosystems DNA sequencer (model 377). Oligonucleotides previ-
ously used for amplification of fragments served as sequencing
primers.
RESULTS
In this study, HCC cell lines formerly described by Schlott et al
(1997) were used for establishing and optimizing three RT-PCR
assays based on the detection of MDM2, GAGE-1, -2, and FHIT
expression. These tests were ultimately applied on liver tissue and
liver cells obtained by fine-needle aspiration.
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is representative for all samples investigated (HCC, FNH, HC).
The PCR fragments obtained from the HCC, FNH and HC
samples were analysed by automatic sequencing and sequence
alignement.  MDM2 point mutations were found exclusively in the
MDM2 transcripts amplified from 3/10 HCC samples (Figure 2).
The MDM2 mutations were located in a zinc-finger domain of
MDM2 and could be divided into two groups. Evidence is given
for a MDM2 mutation that has not been described so far. The
genetic alteration was classified as a mis-sense mutation replacing
the codon CGT by codon AGT. In consequence, the amino acid
residue arginine in mature MDM2 might be converted into serine.
The other two mutations have been described before and represent
a frame-shift mutation inducing a premature stop codon (Schlott
et al, 1997).
Expression of the GAGE-1, -2 genes was found in specimens
from six patients with HCC (Figure 3). The PCR fragments did not
show any gene mutations or deletions according to the data of
automatic sequencing. The other samples (four HCC, ten FNH, ten
normal liver specimens) did not contain GAGE-1, -2 RNA.
Aberrant transcripts were detected by amplifying FHIT RNA in
seven HCC, two FNH and two HC specimens. Transcript sizes
observed in agarose gel ranged from 190 bp to 561 bp (Figure 4).
Because of the enhanced sensitivity of the semi-nested assay even
low abundance transcripts were detected in the specimens. Five
samples (three HCC, two FNH) did not reveal DNA signals corre-
sponding to full length FHIT RNA (Figure 4, HCC sample 2). The
FHIT expression patterns of two HCCs additionally revealed weak
DNA bands larger than the expected size of 561 bp representing
heteroduplexes formed between FHIT-splicing variants.
The nucleotide sequence of the full length FHIT cDNA, or the
various transcripts found in the samples, was determined by auto-
matic sequencing. None of the FHIT mRNAs showed point muta-
tions or nucleotide insertions. In detail, the analysis revealed
transcripts lacking exon 5–8, 4–6, 5–7, 5–6, 4–5, and 8 as described
in former publications (Negrini et al, 1996; Sozzi et al, 1996;
Thiagalingam et al, 1996; Virgilio et al, 1996; Gemma et al, 1997;
Hendricks et al, 1997). Most of these transcript types were found in
HCC and FNH entities under investigation and negative controls.
However, the FHIT transcripts lacking exon 5–7 (264 bp) and exon
5–8 (193 bp) occurred in HCC and FNH, samples but not in normal
hepatocytes. The nucleotide sequence of both mRNAs is shown in
Figure 5. Analysis currently in progress has not yet detected these
FHIT RNA types in non-neoplastic hepatocytes so far.
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Figure 1 Detection of MDM2 mRNA by agarose gel electrophoresis and
ethidium bromide staining. RNA from five HCC samples was used for RT-
PCR with MDM2 primers flanking the zinc-finger domain. –, negative control,
cell line showing absence of MDM2 expression; P: buffer control, no RNA in
the cDNA synthesis
Figure 2 Sequence analysis of two PCR products amplified from MDM2
mRNA isolated from HCC. The wild-type (WT) sequences presented were
obtained from RNA extracted from a FNH sample. Mutant sequence A (MT-
A) obtained from an HCC sample shows mis-sense mutation causing the
codon change ACG ® ACT (sense strand CGT ® AGT). As a result, amino
acid Arg is replaced by Ser. Mutant MDM2 nucleotide sequence B (MT-B)
contains a T-insertion generating a premature stop codon. This frame-shift
mutation was detected in two HCC samples. Arrows indicate point
mutation/nucleotide insertion
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Figure 3 Identification of 244 bp PCR fragments resulting from the GAGE-
1, -2 genes of HCC samples on 3% agarose gel. The DNA fragment was
amplified from six HCC (A–F). The sizes of the markers are shown on the
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130An overview on the expression pattern of HCC aspirates is
demonstrated in Table 1.
DISCUSSION
From a clinical point of view, fine-needle aspiration biopsy is an
important adjunct for diagnosing benign and malignant lesions of
the liver. The cytodiagnostic criteria used for HCC are increased
nucleocytoplasmic (N/C) ratio, trabecular pattern, atypical naked
nuclei, bile production by malignant hepatocytes, multinucleated
tumour cells and absence of bile duct epithelium (Ducatman,
1992). However, morphological changes associated with inflam-
matory and proliferative processes of the liver may often mimic
malignancy in fine-needle aspirates. In particular, the differentia-
tion between well-differentiated HCC and benign reactive condi-
tions (i.e. FNH) can be very difficult in cytodiagnosis (Huebscher
and Young, 1993).
In search for genetic markers associated with malignant liver
neoplasms, benign and malignant cells of human liver were evalu-
ated for genetic alterations concerning the oncogene MDM2, the
GAGE-1, -2 genes, and the candiate tumour suppressor gene FHIT
in the present study. Accordingly, sensitive nested RT-PCR and
automatic laser scanning system were combined to characterize
the expression and mutation of the target genes. Of note, other
genetic techniques formerly used for this purpose, e.g. Southern
blot hybridization and LOH analysis were not taken into consider-
ation since they are difficult to perform on cytological specimens
containing heterogeneous cell populations.
The MDM2 gene of many solid tumours reveals characteristic
genetic alterations; among these, the most frequently recognized is
gene amplification which is referred to as a major factor of MDM2
overexpression and an indicator of malignancy. Concerning liver
neoplasms, amplification of the MDM2 should be a rare event
since studies on hepatoblastoma cells showed non-amplified
MDM2 genes in all samples analysed (Ohnishi et al, 1996).
However, different alterations of MDM2 were detected recently in
two HCC cell lines and further tumour entities, e.g. point muta-
tions in a putative zinc-finger motif of MDM2 (Schlott et al, 1997).
In the present work, the respective assays were transfered to a
larger pool of aspirates containing malignant or benign liver cells.
Expression of the MDM2 gene was detected in all HCC, FNH and
HC samples investigated. Interestingly, MDM2 point mutation was
observed in HCC sample leading to conversion from Arg to Ser or
to the loss of the three zinc-finger motifs. The functional conse-
quences of the amino acid substitution located adjacent to zinc-
finger motif 1 are speculative since NMR and crytallographical
analysis on this phylogenetically conserved domain is lacking.
However, the effects of the T-insertion, which was formerly
detected in two HCC cell lines (Schlott et al, 1997), should be
discussed here in view of current publications. Accordingly, it has
been shown recently for MDM2 protein that the C-terminal RING
domain is involved in the repression of the cyclin-A gene which
controls the transition from G1 to S phase. When transfecting cells
with MDM2 RNA whose zinc-finger domain was deleted, high
levels of cyclin-A (Leveillard and Wasylyk, 1997) often observed
in MDM2 transformed cells, were noted. Moreover, MDM2 tran-
scripts lacking the complete 3¢-end with the three zinc-finger
motifs naturally occur in tumour cells. These transcripts are able to
transform cultivated mouse fibroblasts (Sigalas et al, 1996). Thus,
it might be speculated that MDM2 frame-shift mutations detected
76 T Schlott et al




Figure 4 Analysis of FHIT expression in a panel of liver aspirates on 3%
agarose gel. Each lane shows the PCR fragments produced by RT-PCR and
semi-nested PCR. The lanes contain normal (561 bp) and various aberrant
FHIT transcripts (195 bp, 200 bp, 264 bp, 290 bp, 350 bp, 490 bp) detected
in HCC (lanes 1–5), FNH (lanes 6–9), and two HC (lanes 10, 11) serving as
negative controls. The sizes of the markers are shown on the right
                                                           
           
                                                                             
     
                       
                         
 
Figure 5 Automatic sequencing of two aberrant FHIT transcripts. Fragment
A (264 bp length) lacked exons 5–7. In fragment B (195 bp length) exons
5–8 were deleted. Both types of transcript were found in HCC and FNH, but
not in hepatocytes.
Table 1 Expression analysis of FHIT, GAGE-1, -2, and MDM2 in the
investigated HCC fine-needle aspirates. 
HCC Full length Aberrant FHIT transcript, GAGE-1, -2 MDM2
sample FHIT FHIT exons deleted RNA mutation
No. RNA RNA
1 + + 5–8 + –
2 – + 5–8, 4–6, 5–6 – + (I)
3 – + 5–8, 5–7 – + (C)
4 + + 5–8, 4–5, 8 + –
5 + + 5–6 – –
6 + + 5–8 + –
7 – + 5–8 + –
8 + + 4–5, 8 + –
9 + + 5–8, 4–6, 4–5 + –
10 + + 4–6 – + (I)
I, T-insertion; C, Arg ® Ser conversionin HCC are associated with synthesis of truncated MDM2 proteins
contributing to malignancy. In vitro transfection assays on mouse
hepatocytes might help to prove this hypothesis.
Expression of one of the proteins belonging to the family of
tumour-associated antigens, i.e. MAGE-1, has already been
reported for HCC (Yamashita et al, 1996); however, neoplasms of
the liver have apparently not yet been analysed for the expression
of the GAGE-1, -2 genes. In the present study, GAGE-1, -2 RNA
was detected in 60% of HCC specimens, although some of the
fine-needle aspirates have been stored for years. Interestingly, the
data of Yamashita and co-workers (1996) revealed a comparable
high percentage of MAGE-1 expression (75%) in fresh HCC
samples derived from HCC cell lines and biopsies, respectively.
The results of both studies favour the application of RNA-PCR
assays on various kinds of material.
It is noteworthy that MDM2 mutations were only found in HCC
cells showing absence of the GAGE-1, -2 expression. It suggests
that synthesis of intact MDM2 proteins in HCC is associated with
up-regulation of GAGE-1, -2 genes. However, this fact should be
confirmed by further in vitro experiments on cultivated HCC cells
in order to prove any physiological connection between both
markers.
FHIT was selected for analysis, since former data indicated that
aberrant FHIT transcripts may be potential indicators of malig-
nancy. The present data indicate expression of aberrant FHIT tran-
scripts in malignant as well as in non-malignant liver cells of
archival fine-needle aspirates. This phenomenon is possibly due to
the applying of semi-nested-PCR technique which favoured
amplification of FHIT transcripts produced in small amounts.
While this work was in progress, Chen et al (1998), also detected
aberrant  FHIT transcripts in fresh non-tumorous liver tissue.
Similar results were obtained by other groups in premalignant and
malignant lesions of bronchi, liver and brain (Fong et al, 1997;
Panagopoulos et al, 1997). Taken together, these observations
from different groups working independently still leave the ques-
tion open whether it is possible to relate the detection of FHIT-
splicing variants to malignant transformation.
Concerning liver cells, our data are not conclusive whether a
characteristic FHIT expression pattern exists which might help to
differentiate between non-neoplastic and neoplastic liver cells.
This is due to the fact that two types of FHIT transcript lacking
exons 5–7 and exons 5–8 were detected in HCC and FNH, but not
in the negative controls. Thus, it can be argued that both transcripts
might play a role in proliferation of malignant and non-malignant
liver cells, but further experiments on a larger collection of hepatic
samples are necessary to support this hypothesis. Interestingly,
Fong and co-workers recently detected the transcript lacking exons
5–8 in Epstein–Barr virus-infected cell line and supposed it to be
the result of transformation (Fong et al, 1997).
Other typical genetic alterations were not detectable in malig-
nant and non-malignant liver cell FHIT RNA. Mutations, for
example, which would be reliable indicators for inactivation of the
putative FHIT tumour suppressor, could not be detected in either
the histidine triad motif His-Xaa-HisXaa-His of exon 8, a highly
conserved region possibly involved in binding of zinc ions (Lima
et al, 1996), or in other regions of FHIT amplification products.
These results are in accordance with the data of Sozzi et al (1996)
and Ohta et al (1996), who found FHIT mutations in coding
regions to be rare events.
In summary, the FHIT assay did not allow differentiation
between malignant hepatocytes, benign proliferating hepatocytes
and normal hepatocytes tested in this study. Since formation of
aberrant FHIT RNA appears to be a common feature of benign,
non-neoplastic hepatocytes, the role of FHIT transcripts in hepato-
cellular transformation is elusive. In contrast, MDM2 mutations
and GAGE-1, -2 expression were only present in HCC. Therefore,
it might be of value to investigate whether the two assays can be
used in routine cytodiagnosis of liver lesions.
Taking all demonstrated facts together, one can conclude that
combining the GAGE-1, -2 PCR assay with other PCR assays
based on the detection of other tumour rejection antigens, such as
MAGE-1 and MAGE-3, may further optimize genetic detection of
HCC in cytological material. Studies are currently under progress
to test this hypothesis.
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